324 related articles for article (PubMed ID: 27454287)
1. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
Drost R; Dhillon KK; van der Gulden H; van der Heijden I; Brandsma I; Cruz C; Chondronasiou D; Castroviejo-Bermejo M; Boon U; Schut E; van der Burg E; Wientjens E; Pieterse M; Klijn C; Klarenbeek S; Loayza-Puch F; Elkon R; van Deemter L; Rottenberg S; van de Ven M; Dekkers DH; Demmers JA; van Gent DC; Agami R; Balmaña J; Serra V; Taniguchi T; Bouwman P; Jonkers J
J Clin Invest; 2016 Aug; 126(8):2903-18. PubMed ID: 27454287
[TBL] [Abstract][Full Text] [Related]
2. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
[TBL] [Abstract][Full Text] [Related]
4. RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
Wang Y; Krais JJ; Bernhardy AJ; Nicolas E; Cai KQ; Harrell MI; Kim HH; George E; Swisher EM; Simpkins F; Johnson N
J Clin Invest; 2016 Aug; 126(8):3145-57. PubMed ID: 27454289
[TBL] [Abstract][Full Text] [Related]
5. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Jaspers JE; Kersbergen A; Boon U; Sol W; van Deemter L; Zander SA; Drost R; Wientjens E; Ji J; Aly A; Doroshow JH; Cranston A; Martin NM; Lau A; O'Connor MJ; Ganesan S; Borst P; Jonkers J; Rottenberg S
Cancer Discov; 2013 Jan; 3(1):68-81. PubMed ID: 23103855
[TBL] [Abstract][Full Text] [Related]
6. A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Bouwman P; van der Gulden H; van der Heijden I; Drost R; Klijn CN; Prasetyanti P; Pieterse M; Wientjens E; Seibler J; Hogervorst FB; Jonkers J
Cancer Discov; 2013 Oct; 3(10):1142-55. PubMed ID: 23867111
[TBL] [Abstract][Full Text] [Related]
7. EZH2 Is Overexpressed in
Puppe J; Opdam M; Schouten PC; Jóźwiak K; Lips E; Severson T; van de Ven M; Brambillasca C; Bouwman P; van Tellingen O; Bernards R; Wesseling J; Eichler C; Thangarajah F; Malter W; Pandey GK; Ozretić L; Caldas C; van Lohuizen M; Hauptmann M; Rhiem K; Hahnen E; Reinhardt HC; Büttner R; Mallmann P; Schömig-Markiefka B; Schmutzler R; Linn S; Jonkers J
Clin Cancer Res; 2019 Jul; 25(14):4351-4362. PubMed ID: 31036541
[TBL] [Abstract][Full Text] [Related]
8. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
9. Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Henneman L; van Miltenburg MH; Michalak EM; Braumuller TM; Jaspers JE; Drenth AP; de Korte-Grimmerink R; Gogola E; Szuhai K; Schlicker A; Bin Ali R; Pritchard C; Huijbers IJ; Berns A; Rottenberg S; Jonkers J
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8409-14. PubMed ID: 26100884
[TBL] [Abstract][Full Text] [Related]
10. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
11. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
[TBL] [Abstract][Full Text] [Related]
12. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
McMullin RP; Wittner BS; Yang C; Denton-Schneider BR; Hicks D; Singavarapu R; Moulis S; Lee J; Akbari MR; Narod SA; Aldape KD; Steeg PS; Ramaswamy S; Sgroi DC
Breast Cancer Res; 2014 Mar; 16(2):R25. PubMed ID: 24625110
[TBL] [Abstract][Full Text] [Related]
13. Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.
Vaclová T; Woods NT; Megías D; Gomez-Lopez S; Setién F; García Bueno JM; Macías JA; Barroso A; Urioste M; Esteller M; Monteiro ANA; Benítez J; Osorio A
Hum Mol Genet; 2016 Dec; 25(24):5287-5299. PubMed ID: 27742776
[TBL] [Abstract][Full Text] [Related]
14. Olaparib for the treatment of breast cancer.
Robert M; Frenel JS; Gourmelon C; Patsouris A; Augereau P; Campone M
Expert Opin Investig Drugs; 2017 Jun; 26(6):751-759. PubMed ID: 28395540
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
Ter Brugge P; Kristel P; van der Burg E; Boon U; de Maaker M; Lips E; Mulder L; de Ruiter J; Moutinho C; Gevensleben H; Marangoni E; Majewski I; Józwiak K; Kloosterman W; van Roosmalen M; Duran K; Hogervorst F; Turner N; Esteller M; Cuppen E; Wesseling J; Jonkers J
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381626
[TBL] [Abstract][Full Text] [Related]
16. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
Wang W; Figg WD
Cancer Biol Ther; 2008 Jul; 7(7):1004-5. PubMed ID: 18720553
[TBL] [Abstract][Full Text] [Related]
17. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
[TBL] [Abstract][Full Text] [Related]
18. Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
Choi YE; Meghani K; Brault ME; Leclerc L; He YJ; Day TA; Elias KM; Drapkin R; Weinstock DM; Dao F; Shih KK; Matulonis U; Levine DA; Konstantinopoulos PA; Chowdhury D
Cell Rep; 2016 Jan; 14(3):429-439. PubMed ID: 26774475
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
Drost R; Bouwman P; Rottenberg S; Boon U; Schut E; Klarenbeek S; Klijn C; van der Heijden I; van der Gulden H; Wientjens E; Pieterse M; Catteau A; Green P; Solomon E; Morris JR; Jonkers J
Cancer Cell; 2011 Dec; 20(6):797-809. PubMed ID: 22172724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
